Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Safety and efficacy of new TKIs in Ph+ ALL

Usman Ali Akbar • 19 Apr 2022
The 2022 Tandem Meetings
Acute Lymphoblastic Leukemia Leukemia Dasatinib Ponatinib

Usman Ali Akbar, MBBS, University of Louisville, Louisville, KY, comments on the efficacy and toxicity profile of new tyrosine kinase inhibitors (TKIs) as compared to older TKIs and chemotherapy in the treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Newer TKIs are more efficacious and are associated with fewer side effects than older TKIs and chemotherapy. Nevertheless, randomized clinical trials are required to incorporate these drugs in the treatment algorithm of Ph+ ALL. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Usman Ali Akbar

Can alloHSCT be avoided in Ph+ ALL?
0:52
Can alloHSCT be avoided in Ph+ ALL?
Usman Ali Akbar • 19 Apr 2022
Monoclonal antibodies for the treatment of adult ALL
0:58
Monoclonal antibodies for the treatment of adult ALL
Usman Ali Akbar • 19 Apr 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals